Testosterone Cypionate: Compounded vs. Branded, A Complete Clinical Comparison

What is the difference between branded and compounded testosterone cypionate?

Depo-Testosterone is an FDA-approved prescription testosterone cypionate product for replacement therapy in men with primary or hypogonadotropic hypogonadism [1]. FDA approval includes review of the manufacturer's cGMP compliance [6], and FDA's drug approval process is what consumers and health care professionals rely on for verification of safety, effectiveness and quality [2]. The label sets the dose, route, warnings and monitoring for that product [1].

Compounded testosterone cypionate is prepared by a compounder and is not FDA-approved [2]. FDA says it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [2]. A compounded drug may serve a patient whose medical need cannot be met by an FDA-approved drug, for example an allergy to a dye, but it does not carry approval status [2].

FDA also draws a line between generic and compounded drugs. A generic drug is FDA-approved and must establish therapeutic equivalence to a brand-name drug; a compounded drug is not FDA-approved [2].

Day-to-day oversight of state-licensed pharmacies that compound generally rests with state boards of pharmacy [2]. Outsourcing facilities are primarily overseen by FDA and are subject to cGMP requirements [2].

What does the Depo-Testosterone label specify?

The Depo-Testosterone label specifies deep gluteal intramuscular injection only, never intravenous, at 50 to 400 mg every 2 to 4 weeks for hypogonadal men [1]. It is supplied as 100 mg/mL and 200 mg/mL and contains cottonseed oil, benzyl benzoate and benzyl alcohol preservative [1]. Before starting, the label says to confirm hypogonadism with morning serum testosterone measured on at least two separate days, both below the normal range [1]. The half-life after intramuscular injection is about 8 days [1]. The Endocrine Society guideline likewise recommends diagnosing hypogonadism only with symptoms and consistently low serum testosterone, and confirming with repeat morning total testosterone [7].

The label says dose is adjusted according to response and adverse reactions, and to check hemoglobin and hematocrit periodically during long-term use [1].

The label lists contraindications: hypersensitivity, men with breast carcinoma, men with known or suspected prostate carcinoma, pregnant women, and patients with serious cardiac, hepatic or renal disease [1].

What safety issues apply to both forms?

Testosterone therapy can raise blood pressure. FDA says ambulatory blood pressure studies confirmed an increase with all testosterone products, class-wide [9]. The Depo-Testosterone label says testosterone can increase blood pressure, which can increase cardiovascular risk over time, that blood pressure should be monitored periodically, and that testosterone products are not recommended in uncontrolled hypertension [1].

Cardiovascular label language is not identical across products. The Depo-Testosterone label does not mention TRAVERSE and still says long-term clinical safety trials have not been conducted, that epidemiologic studies and randomized trials have been inconclusive for major adverse cardiovascular events, and that some studies, but not all, have reported an increased risk [1]. TRAVERSE tested daily 1.62% testosterone gel, not an injection, in 5,246 men aged 45 to 80 with hypogonadism and preexisting or high cardiovascular risk [4]. Over a mean treatment of 21.7 months and mean follow-up of 33 months, the primary MACE rate was 7.0% with testosterone gel versus 7.3% with placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17), meeting noninferiority [4].

Hematocrit is another route-related issue. A network meta-analysis of 29 placebo-controlled randomized trials in 3,393 men found intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% (95% CI 2.9 to 5.1) versus placebo [5]. A retrospective review of 178 hypogonadal men found erythrocytosis, defined as hematocrit above 50%, in 66.7% of men on injectable testosterone versus 12.8% on gels; the injection group was younger and had higher baseline hematocrit, and the study was not randomized [10]. These findings concern the injectable route, not whether the vial is branded or compounded.

The Depo-Testosterone label also lists venous thromboembolism, gynecomastia that may persist, polycythemia, injection site pain and inflammation, and other reactions [1]. It says androgens may increase sensitivity to oral anticoagulants and may lower blood glucose and insulin requirements [1].

Is compounded testosterone cypionate as effective as branded?

FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before marketing [2]. It also warns that poor compounding practices can result in contamination or a drug that contains too much or too little active ingredient, which can lead to serious patient injury [2]. A branded product has FDA-reviewed manufacturing and a label that sets its dose and warnings [1][6].

Is Depo-Testosterone approved for age-related low testosterone?

The Depo-Testosterone label says safety and efficacy in men with age-related hypogonadism, also called late-onset hypogonadism, have not been established [1]. FDA says none of the approved testosterone products are approved for men with low testosterone who lack an associated medical condition [11]. In June 2026, FDA asked for label updates that would remove that limitation of use and revise prostate cancer and benign prostatic hyperplasia safety information [11]. The Depo-Testosterone label (effective 2026-08-21) still carries the older limitation text [1].